RESUMO
Alopecia areata (AA) frequently occur in association with other autoimmune diseases such as thyroid disorders, anemias and other skin disorders with autoimmune etiology. Despite numerous studies related to individual disease associations in alopecia areata, there is paucity of literature regarding comprehensive studies on concomitant cutaneous and systemic diseases. The present study has been designed to determine if there is a significant association between alopecia areata and other autoimmune diseases. This study covers 71 patients with the diagnosis of alopecia areata as the case group and 71 patients with no evidence of alopecia areata as the control group. Among the cutaneous diseases associated with AA, atopic dermatitis (AD) showed maximum frequency with an O/E ratio of 2.5, which indicates that it is two to three times more common in patients with alopecia areata. In our study, thyroid disorders showed the highest frequency with on O/E ratio of 3.2 and a P value of 0.01, which is statistically highly significant. Among the thyroid disorders, hypothyroidism was the most frequent association (14.1%) in our study. Since systemic involvement is not infrequent in patients with alopecia areata, it is imperative to screen these patients for associated disorders, particularly atopy, thyroid diseases, anemias and other autoimmune disorders, especially if alopecia areata is chronic, recurrent and extensive.
Assuntos
Doenças do Ânus/diagnóstico , Condiloma Acuminado/diagnóstico , Administração Tópica , Doenças do Ânus/tratamento farmacológico , Condiloma Acuminado/tratamento farmacológico , Intervalo Livre de Doença , Humanos , Lactente , Masculino , Fitoterapia , Plantas Medicinais , Plantas Tóxicas , Podophyllum/uso terapêuticoRESUMO
Three cases (two male, one female) of botryomycosis are reported. All were adults and had no predisposing factors or immunosuppression. Staphylococcus, Pesudomonas and E coli were grown on bacterial culture. Patients were treated with antibiotics based on the sensitivity pattern with fairly good response. No systemic involvement was present in any case.
RESUMO
Pedal edema as a possible adverse effect of clofazimine therapy in leprosy was first reported in 1990. Raasch, et al. reported their lymphangiographic findings on ten patients who had clinical lepromatous leprosy in 1969. None of these patients had been on clofazimine therapy. Our study, therefore, was designed to assess the changes that might be seen in the lymphatic system of patients treated with clofazimine for the management of leprosy. Our findings are compared with those of Raasch and his colleagues.
